{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:58:38Z","timestamp":1793692718067,"version":"4.5.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022544","name":"Samsung Biomedical Research Institute","doi-asserted-by":"publisher","award":["OTA2301971"],"award-info":[{"award-number":["OTA2301971"]}],"id":[{"id":"10.13039\/501100022544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ekir.2025.06.036","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:27:18Z","timestamp":1750879638000},"page":"3181-3191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Protective Effects of SGLT-2 Inhibitors Against Postoperative Acute Kidney Injury in Type 2 Diabetes"],"prefix":"10.1016","volume":"10","author":[{"given":"Seung Min","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyoung","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junseok","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Man","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryoun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooseong","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.06.036_bib1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.036_bib2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.036_bib3","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.036_bib4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.036_bib5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.036_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.036_bib7","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.036_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.036_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneph.2016.159","article-title":"Acute kidney injury from SGLT2 inhibitors: potential mechanisms","volume":"12","author":"Hahn","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.06.036_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0453","article-title":"Sodium-glucose transport Protein 2 inhibitor use for type 2 diabetes and the incidence of acute kidney injury in Taiwan","volume":"6","author":"Chung","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2025.06.036_bib11","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1053\/j.ajkd.2021.09.015","article-title":"SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes","volume":"79","author":"Zhuo","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.06.036_bib12","doi-asserted-by":"crossref","first-page":"E351","DOI":"10.1503\/cmaj.191283","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study","volume":"192","author":"Iskander","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.ekir.2025.06.036_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.781379","article-title":"Comparison of adverse kidney outcomes with empagliflozin and linagliptin use in patients with Type 2 diabetic patients in a real-world setting","volume":"12","author":"Lee","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2025.06.036_bib14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2215\/CJN.16541221","article-title":"Postoperative acute kidney injury","volume":"17","author":"Boyer","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.036_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2403769","article-title":"A randomized trial of intravenous amino acids for kidney protection","volume":"391","author":"Landoni","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.036_bib16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bja.2017.12.018","article-title":"Effect of goal-directed haemodynamic therapy on postoperative complications in low-moderate risk surgical patients: a multicentre randomised controlled trial (FEDORA trial)","volume":"120","author":"Calvo-Vecino","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ekir.2025.06.036_bib17","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2025.06.036_bib18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41581-021-00418-2","article-title":"Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative","volume":"17","author":"Prowle","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.06.036_bib19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2025.06.036_bib20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1681\/ASN.2018070757","article-title":"Simple postoperative AKI risk (SPARK) classification before noncardiac surgery: a prediction index development study with external validation","volume":"30","author":"Park","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.036_bib21","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/dom.13754","article-title":"Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials","volume":"21","author":"Gilbert","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2025.06.036_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLOS Med"},{"key":"10.1016\/j.ekir.2025.06.036_bib23","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.06.036_bib24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.06.036_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2215\/CJN.11220720","article-title":"Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury","volume":"16","author":"Zhao","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.036_bib26","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3389\/fendo.2019.00820","article-title":"Renal and glucose-lowering effects of empagliflozin and dapagliflozin in different chronic kidney disease stages","volume":"10","author":"Lin","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ekir.2025.06.036_bib27","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.06.036_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.06.036_bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.06.036_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2020.05.014","article-title":"We can finally stop worrying about SGLT2 inhibitors and acute kidney injury","volume":"76","author":"Sridhar","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.06.036_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.036_bib32","doi-asserted-by":"crossref","first-page":"686","DOI":"10.23876\/j.krcp.23.001","article-title":"Acute kidney disease: an overview of the epidemiology, pathophysiology, and management","volume":"42","author":"Kung","year":"2023","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.ekir.2025.06.036_bib33","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/ehf2.13955","article-title":"Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure","volume":"9","author":"Thiele","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ekir.2025.06.036_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae229","article-title":"EValuating the Effect of periopeRaTIve empaGliflOzin on cardiac surgery associated acute kidney injury: rationale and design of the VERTIGO study","volume":"17","author":"Coca","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.06.036_bib35","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/bjs.10498","article-title":"Acute kidney injury and mortality 1 year after major non-cardiac surgery","volume":"104","author":"O\u2019Connor","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.ekir.2025.06.036_bib36","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41401-024-01265-0","article-title":"Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway","volume":"45","author":"Ni","year":"2024","journal-title":"Acta Pharmacol Sin"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925004085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925004085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:41:35Z","timestamp":1758130895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925004085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2468024925004085"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.06.036","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Protective Effects of SGLT-2 Inhibitors Against Postoperative Acute Kidney Injury in Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.06.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}